

## **PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE {LABEL}**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Locaine 2% w/v Solution for injection.

### **2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Injectable solution containing:

Lidocaine hydrochloride Ph.Eur.	2%w/v
Adrenaline acid tartrate	0.00227 %w/v
Preservative: Chlorocresol	0.1%w/v
Sodium metabisulphite,	0.1%w/v

### **3. PHARMACEUTICAL FORM**

A colourless to pale yellow solution for injection.

### **4. PACKAGE SIZE**

100 ml

### **5. TARGET SPECIES**

Horses

### **6. INDICATION(S)**

Local anaesthetic for parenteral administration to horses.

### **7. METHOD AND ROUTE(S) OF ADMINISTRATION**

For intramuscular and subcutaneous injection only.

For further information on dosage see package leaflet.

### **8. WITHDRAWAL PERIOD**

Not to be used in horses intended for human consumption.

Treated horses may never be slaughtered for human consumption.

The horse must have been declared as not intended for human consumption under national horse passport legislation.

**9. SPECIAL WARNING(S), IF NECESSARY**

Avoid accidental intravascular injection

**USER WARNING:** If accidental self-injection or ingestion occurs, seek medical advice immediately. See package leaflet for full information

**10. EXPIRY DATE**

Exp: dd/mm/yy

Once broached use by: \_\_\_/\_\_\_/\_\_\_

**11. SPECIAL STORAGE CONDITIONS**

Following withdrawal of the first dose, use the product within 28 days. Discard any unused material.

Do not store above 25°C.

Protect from light.

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE**

For Animal Treatment Only.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the reach and sight of children.

POM-VPS To be supplied only on veterinary prescription.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 02000/4228

**17. MANUFACTURER’S BATCH NUMBER**

Bn.:  
D.O.M

Distributed by:  
Animalcare Ltd  
10 Great North Way  
York  
YO26 6RB

**PACKAGE LEAFLET FOR: Locaine 2% w/v Solution for Injection**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Norbrook Laboratories Limited  
Newry  
Co. Down  
BT35 6JP  
Northern Ireland

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Locaine 2% w/v Solution for injection.

**3. STATEMENT OF THE ACTIVE SUBSTANCE (S) AND OTHER INGREDIENTS**

A bright almost colourless solution containing:

Lidocaine hydrochloride	2%w/v
Adrenaline acid tartrate	0.00227%w/v
Antimicrobial preservative: Chlorocresol	0.1% w/v
Sodium metabisulphite,	0.1%w/v

**4. INDICATION(S)**

Local anaesthetic for parenteral administration to horses. It may be used for infiltration anaesthesia (local or field block) and regional anaesthesia including paravertebral nerve blocks.

**5. CONTRAINDICATIONS**

Avoid accidental intravascular injection.

**6. ADVERSE REACTIONS**

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Horses

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

For intramuscular and subcutaneous injection only.

### **1. Local infiltration and field block anaesthesia:**

The recommended dose is;

Horses: up to 100-200 ml per surgical site

In cases of repeated administration, the total volume administered should not exceed 0.5 ml/kg bodyweight.

### **2. Regional anaesthesia:**

Paravertebral anaesthesia: Approx 7 ml per site

## **9. ADVICE ON CORRECT ADMINISTRATION**

Care should be taken in the administration of repeat doses in cases where the desired degree of anaesthesia has not been attained.

## **10. WITHDRAWAL PERIOD(S)**

Not to be used in horses intended for human consumption.

Treated horses may never be slaughtered for human consumption.

The horse must have been declared as not intended for human consumption under national horse passport legislation.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the reach and sight of children.

Protect from light.

Do not store above 25°C.

For animal treatment only.

Following withdrawal of the first dose, use the product within 28 days. Discard any unused material.

When the container is broached (opened) for the first time, the date on which any product remaining in the container should be discarded should be calculated. A statement of the in-use shelf life of the product is given on this package leaflet. This discard date should be written in the space provided on the label.

## **12. SPECIAL WARNING(S)**

**USER WARNINGS:** If accidental self-injection or ingestion occurs, seek medical advice immediately.

In case of eye contamination or excessive skin contact, irrigate/ wash immediately with plenty of clean water. Seek medical attention if irritation persists.

Wash hands after use.

In mild cases of overdose, animals become anxious and restless. The symptoms are transient and will pass off with little or no treatment being necessary. In severe cases of overdose convulsions may occur, and respiratory and circulatory failure may follow. Overdosage may be treated by administering respiratory stimulants and keeping animals warm.

## **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Dispose of any unused or empty containers in accordance with guidance from your local waste regulation authority.

## **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

July 2013

## **15. OTHER INFORMATION**

ManA:2000  
Vm 02000/4228


### **Package Quantities**

Multidose vials of 100 ml.

POM-VPS To be supplied only by veterinary prescription.

**Distributed by:**  
Animalcare Ltd  
10 Great North Way  
York  
YO26 6RB

**Approved: 03/08/2017**

A handwritten signature in black ink, appearing to read 'J. Long', positioned below the approval date.